Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 30 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 30 Oct 2008 Actual patient number (420) added as reported by ClinicalTrials.gov.